Association of aspirin and nonaspirin nonsteroidal anti-inflammatory drugs with cancer incidence and mortality

被引:68
作者
Bardia, Aditya
Ebbert, Jon O.
Vierkant, Robert A.
Limburg, Paul J.
Anderson, Kristin
Wang, Alice H.
Olson, Janet E.
Vachon, Celine M.
Cerhan, James R.
机构
[1] Mayo Clin, Coll Med, Dept Internal Med, Rochester, MN 55905 USA
[2] Mayo Clin, Coll Med, Dept Hlth Sci Res, Rochester, MN 55905 USA
[3] Univ Minnesota, Dept Epidemiol, Minneapolis, MN USA
来源
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE | 2007年 / 99卷 / 11期
关键词
D O I
10.1093/jnci/djk200
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background The cancer chemopreventive benefits of aspirin and nonaspirin nonsteroidal anti-inflammatory drugs (NSAIDs) are incompletely defined and may vary by smoking history. We evaluated associations between aspirin and nonaspirin NSAID use with cancer incidence and mortality stratified by smoking history in the Iowa Women's Health Study, a prospective cohort of postmenopausal women. Methods Aspirin and nonaspirin NSAID use was self-reported by questionnaire in 1992. Cancer incidence and mortality were ascertained by annual linkage to the Iowa Surveillance, Epidemiology, and End Results Cancer Registry and death certificates. Cox proportional hazards models were used to estimate multivariable relative risks (RRs) and 95% confidence intervals (Cis). All statistical tests were two-sided. Results During an average of 10 years of follow-up, 3487 incident cancer cases and 3581 deaths were observed in the cohort of 22507 women. Compared with nonuse, aspirin use was inversely associated with total cancer incidence (multivariable-adjusted RR = 0.84, 95% Cl = 0.77 to 0.90), with age-adjusted incidence rates of 147 and 170 per 10000 person-years for ever and never users, respectively, and was inversely associated with cancer mortality (multivariable-adjusted RR = 0.87, 95% Cl = 0.76 to 0.99), with age-adjusted rates of 47 and 52 per 10000 person-years. The inverse relationship was stronger among former and never smokers than current smokers, although not statistically significantly (P=.28). Aspirin use was also inversely associated with coronary heart disease mortality (multivariable-adjusted RR = 0.75, 95% Cl = 0.64 to 0.89), with age-adjusted rates of 23 and 30 per 10000 person-years for ever and never users, respectively, and with all-cause mortality (multivariable-adjusted RR = 0.82, 95% Cl = 0.76 to 0.89), with age-adjusted rates of 126 and 155 per 10000 person-years. Nonaspirin NSAID use was not associated with cancer incidence or mortality, coronary heart disease mortality, or all-cause mortality. Conclusions Aspirin use, but not nonaspirin NSAID use, was associated with lower risks of cancer incidence and mortality, which was more pronounced among former and never smokers than current smokers.
引用
收藏
页码:881 / 889
页数:9
相关论文
共 65 条
[1]   The association between aspirin use and the incidence of colorectal cancer in women [J].
Allison, Matthew ;
Garland, Cedric ;
Chlebowski, Rowan ;
Criqui, Michael ;
Langer, Robert ;
Wu, Lieling ;
Roy, Hemant ;
McTiernan, Anne ;
Kuller, Lewis .
AMERICAN JOURNAL OF EPIDEMIOLOGY, 2006, 164 (06) :567-575
[2]  
Alpha-Tocopherol Beta Carotene Cancer Prevention Study Group, 1994, N Engl J Med, V330, P1029, DOI 10.1056/NEJM199404143301501
[3]  
Anderson KE, 2002, J NATL CANCER I, V94, P1168, DOI 10.1093/jnci/94.15.1168
[4]  
[Anonymous], INT STAT CLASS DIS R
[5]  
[Anonymous], 1977, INT CLASS DIS
[6]   Celecoxib for the prevention of colorectal adenomatous polyps [J].
Arber, Nadir ;
Eagle, Craig J. ;
Spicak, Julius ;
Racz, Istvan ;
Dite, Petr ;
Hajer, Jan ;
Zavoral, Miroslav ;
Lechuga, Maria J. ;
Gerletti, Paola ;
Tang, Jie ;
Rosenstein, Rebecca B. ;
Macdonald, Katie ;
Bhadra, Pritha ;
Fowler, Robert ;
Wittes, Janet ;
Zauber, Ann G. ;
Solomon, Scott D. ;
Levin, Bernard .
NEW ENGLAND JOURNAL OF MEDICINE, 2006, 355 (09) :885-895
[7]   Nonsteroidal anti-inflammatory drugs and aspirin for the prevention of colorectal adenomas and cancer: A systematic review [J].
Asano, TK ;
McLeod, RS .
DISEASES OF THE COLON & RECTUM, 2004, 47 (05) :665-673
[8]   A randomized trial of aspirin to prevent colorectal adenomas [J].
Baron, JA ;
Cole, BF ;
Sandler, RS ;
Haile, RW ;
Ahnen, D ;
Bresalier, R ;
McKeown-Eyssen, G ;
Summers, RW ;
Rothstein, R ;
Burke, CA ;
Snover, DC ;
Church, TR ;
Allen, JI ;
Beach, M ;
Beck, GJ ;
Bond, JH ;
Byers, T ;
Greenberg, ER ;
Mandel, JS ;
Marcon, N ;
Mott, LA ;
Pearson, L ;
Saibil, F ;
van Stolk, RU .
NEW ENGLAND JOURNAL OF MEDICINE, 2003, 348 (10) :891-899
[9]   Daily soluble aspirin and prevention of colorectal adenoma recurrence: One-year results of the APACC trial [J].
Benamouzig, R ;
Deyra, J ;
Martin, A ;
Girard, B ;
Jullian, E ;
Piednoir, B ;
Couturier, D ;
Coste, T ;
Little, J ;
Chaussade, S .
GASTROENTEROLOGY, 2003, 125 (02) :328-336
[10]   METHODS OF ADJUSTMENT FOR ESTIMATING THE ATTRIBUTABLE RISK IN CASE-CONTROL STUDIES - A REVIEW [J].
BENICHOU, J .
STATISTICS IN MEDICINE, 1991, 10 (11) :1753-1773